NeuExcell's ATN ASTROCYTES TO NEURONS^TM Platform Redefines Neural Regeneration

For decades, the prevailing belief in neuroregeneration field has been that neurons cannot be repaired or replaced in human brain. NeuExcell challenges this dogma with innovative ATN™ (Astrocytes-to-Neurons) platform technology by harnessing brain's internal glial cells to regenerate functional, fully integrated neurons at the site of injury through NeuroD1 AAV-based gene therapy.

This revolutionary approach has the potential to address a wide range of neurological conditions, including Alzheimer's disease (AD), stroke, glioma, Parkinson's disease, Huntington's disease, traumatic brain injury, spinal cord injury, ALS, and ocular diseases. Supported by more than a decade of preclinical studies in rodents and non-human primates, we have initiated three first-in-class clinical trials in AD, glioma, and stroke.

By unlocking the brain's internal regenerative capacity, NeuExcell aims to transform the treatment of neurodegenerative diseases and offer new hope for millions of patients worldwide.